CClinicalTrials.gg
CompletedNCT00627367Updated Apr 5, 2018Results posted

Protocolized vs Nonprotocolized Treatment of Adult ED Patients With Acute Severe Pain

A Phase 3 interventional study of Hydromorphone and Nonprotocolized in Acute Pain, sponsored by Montefiore Medical Center. Completed at 1 site in United States. Open to participants aged 21 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-04-05.

Sponsored by Montefiore Medical Center · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
224
Allocation
Randomized
Ages
21 Years to 64 Years
Sex
All
01

Study summary

Patients treated with protocolized pain management (1 mg of IV hydromorphone followed by an additional 1 mg IV hydromorphone if the patient wants more) will have better pain relief and no more adverse events than patients receiving non-protocolized pain management.

02

Conditions studied

  • Acute Pain

Browse trials for

Keywords

  • Acute Pain, Emergency Department, ED, Hydromorphone, Dilaudid Protocolized Nonprotocolized Usual Care
03

In context

Acute Pain

876 studies on the registry are indexed under Acute Pain; 154 are open to participants now.

This study's enrollment of 224 is above the median of 90 across 732 interventional studies indexed under Acute Pain.

Browse Acute Pain studies →

Lead sponsor

Montefiore Medical Center is the lead sponsor of 402 studies on the registry; 70 are open to participants now.

Of its 81 completed or terminated interventional studies of FDA-regulated products, 73 (90%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  1. Age 21 to 64 years: Patients under the age of 21 are automatically triaged to the Children's Hospital at Montefiore Emergency Department, and hence cannot be enrolled in this study. Age 64 was selected as an upper range for inclusion because substantial evidence supports age as being an important determinant of morphine requirement over longer periods of time.
  2. Pain with onset within 7 days: Pain within seven days is the definition of acute pain that has been used in ED literature.
  3. Emergency Department (ED) attending physician's judgment that patient's pain warrants use of intravenous opioids: The factors that influence the decision to use intravenous opioids are complex and extensive. An approach that is commonly taken to address the issue of patient selection in drug trials is to use a specific condition (e.g., renal colic) or treatment (e.g., post-hysterectomy) that would generally be thought to be appropriately treated with an opioid analgesic, thereby eliminating individual judgment about eligibility for the study. However in order to assess the role of intravenous (IV) opioids with the widest generalizability in the ED setting, we decided to enroll patients with a variety of diagnoses, all with a complaint of acute pain. Opioids are not an appropriate treatment for all patients who present with a complaint of pain (e.g., gastroenteritis, migraine). Therefore either a comprehensive list of diagnoses and situations in which opioids are indicated must be specified, or clinical judgment needs to be used. We have opted for the latter alternative.
  4. Normal mental status: In order to provide measures of pain experienced the patient needs to have a normal mental status. Orientation to person, place and time will be used as an indicator of sufficiently normal mental status to participate in the study.

Exclusion criteria

Exclusion Criteria:

  1. Prior use of methadone: the effect of methadone use on the perception of acute pain is unknown and suspected to be altered.
  2. Use of other opioids, tramadol, or heroin in the past seven days: to avoid introducing bias related to opioid tolerance that may alter the response to intravenous opioids thereby masking the effects of the medications administered.
  3. Prior adverse reaction to morphine, hydromorphone, or other opioids: An exception will be if the patient has received opioid medications in the past without adverse event (i.e. a patient may state he is allergic to morphine but has received hydromorphone in the past without any adverse effects)
  4. Chronic pain syndrome: frequently recurrent or daily pain for at least 3 months resulting in alteration in pain perception which is thought to be due to down-regulation of pain receptors. Examples of chronic pain syndromes include sickle cell anemia, osteoarthritis, fibromyalgia, migraine, and peripheral neuropathies.
  5. Alcohol intoxication: the presence of alcohol intoxication may alter the perception, report, and treatment of pain. Alcohol intoxication will be determined to exist as judged by the treating physician.
  6. Systolic Blood Pressure \< 90 mm Hg: Opioids produce peripheral vasodilation that may result in orthostatic hypotension or syncope.
  7. Use of monoamine oxidase (MAO) inhibitors in past 30 days: MAO inhibitors have been reported to intensify the effects of at least one opioid drug causing anxiety, confusion and significant depression of respiration or coma.
  8. Weight less than 100 pounds: we are concerned that hydromorphone in doses up to 2 mg may not be safe in patients weighing less than 100 lbs.
  9. Baseline room air oxygen saturation less than 95%: since IV opioids may cause respiratory depression and result in hypoxemia, we are excluding this subgroup of patients.
  10. C02 measurement greater than 46: In accordance with a similar study (04-12-360), four subsets of patients will have their CO2 measured using a handheld capnometer prior to enrollment in the study. If the CO2 measurement is greater than 46, then the patient will be excluded from the study. The 4 subsets are as follows:

    1. All patients who have a history of chronic obstructive pulmonary disease (COPD)
    2. All patients who have a history of sleep apnea
    3. All patients who report a history of asthma together with greater than a 20 pack-year smoking history
    4. All patients reporting less than a 20 pack-year smoking history who are having an asthma exacerbation
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
224 participants (actual)

Study arms

  • Experimental
    Protocolized

    1mg IV hydromorphone followed by an additional 1mg at 15 minutes if the patient answer "yes" to the question, "Do you want more pain medication?"

    Drug: Hydromorphone

  • Active comparator
    Nonprotocolized

    An IV opioid the type and dose of which will be determined by the treating clincian

    Drug: Nonprotocolized

Interventions

  • DrugHydromorphone

    Hydromorphone 1mg IV, followed by an optional dose of 1mg IV hydromorphone 15 minutes

    Also known as: Dilaudid

  • DrugNonprotocolized

    An IV opioid the type and dose of which will be determined by the treating clinician

    Also known as: Usual Care

06

What researchers measure

Primary outcomes

  1. Patient Reported Change in Pain Intensity From Initial Administration of Analgesics (Baseline) to 60 Minutes Post-baseline.

    Pain intensity is rated on the numerical rating scale (NRS), measured in integer units from 0 ("no pain") to 10 ("worst pain imaginable"). The change in pain intensity subtracts the NRS score given by the patient 60 minutes after treatment was administered from the baseline NRS score (before treatment in the Emergency Department).

    Time frame: 60 minutes

07

Results

Posted Apr 5, 2018

Participant flow

Participant flow — Overall Study
MilestoneProtocolizedNonprotocolized
Started112112
Completed112112
Not completed00

Outcome measures

PrimaryPatient Reported Change in Pain Intensity From Initial Administration of Analgesics (Baseline) to 60 Minutes Post-baseline.

Pain intensity is rated on the numerical rating scale (NRS), measured in integer units from 0 ("no pain") to 10 ("worst pain imaginable"). The change in pain intensity subtracts the NRS score given by the patient 60 minutes after treatment was administered from the baseline NRS score (before treatment in the Emergency Department).

Time frame:
60 minutes
Reported as:
Mean · units on a scale
Patient Reported Change in Pain Intensity From Initial Administration of Analgesics (Baseline) to 60 Minutes Post-baseline.
units on a scaleProtocolizedNonprotocolized
Patient Reported Change in Pain Intensity From Initial Administration of Analgesics (Baseline) to 60 Minutes Post-baseline.5.5 ± 2.94.5 ± 3.0
Post-hocChange in Numerical Rating Scale (NRS) Scores Among Patients Who Received 1 Dose of Intravenous (IV) Hydromorphone

Pain intensity is rated on the numerical rating scale (NRS), measured in integer units from 0 ("no pain") to 10 ("worst pain imaginable"). The change in pain intensity subtracts the NRS score given by the patient 60 minutes after treatment was administered from the baseline score (before treatment in the Emergency Department).

Time frame:
60 minutes
Reported as:
Median · units on a scale
Change in Numerical Rating Scale (NRS) Scores Among Patients Who Received 1 Dose of Intravenous (IV) Hydromorphone
units on a scaleProtocolizedNonprotocolized
Change in Numerical Rating Scale (NRS) Scores Among Patients Who Received 1 Dose of Intravenous (IV) Hydromorphone6.1 ± 4.04.5 ± 3.1
Post-hocChange in Numerical Rating Scale (NRS) Scores Among Patients Who Received 2 Doses of Intravenous (IV) Hydromorphone

Pain intensity is rated on the numerical rating scale (NRS), measured in integer units from 0 ("no pain") to 10 ("worst pain imaginable"). The change in pain intensity subtracts the NRS score given by the patient 60 minutes after treatment was administered from the baseline score (before treatment in the Emergency Department).

Time frame:
60 minutes
Reported as:
Mean · units on a scale
Change in Numerical Rating Scale (NRS) Scores Among Patients Who Received 2 Doses of Intravenous (IV) Hydromorphone
units on a scaleProtocolizedNonprotocolized
Change in Numerical Rating Scale (NRS) Scores Among Patients Who Received 2 Doses of Intravenous (IV) Hydromorphone4.0 ± 3.24.3 ± 3.3
Post-hocChange in Numerical Rating Scale (NRS) Scores Among Patients in the Protocolized Group vs Those in the Physician Driven Group Who Received Only Intravenous (IV) Morphine

Pain intensity is rated on the numerical rating scale (NRS), measured in integer units from 0 ("no pain") to 10 ("worst pain imaginable"). The change in pain intensity subtracts the NRS score given by the patient 60 minutes after treatment was administered from the baseline score (before treatment in the Emergency Department). The comparison of hydromorphone to morphine is due to the wide use of morphine for pain management in the Emergency Department setting and the comparison of the two opioids in previous studies.

Time frame:
60 minutes
Reported as:
Mean · units on a scale
Change in Numerical Rating Scale (NRS) Scores Among Patients in the Protocolized Group vs Those in the Physician Driven Group Who Received Only Intravenous (IV) Morphine
units on a scaleProtocolizedNonprotocolized
Change in Numerical Rating Scale (NRS) Scores Among Patients in the Protocolized Group vs Those in the Physician Driven Group Who Received Only Intravenous (IV) Morphine5.6 ± 3.24.4 ± 2.8

Adverse events

Collected over 60 minutes after the last dose of opioids was given. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Protocolized0/108 (0%)0/108 (0%)33/108 (30.6%)
Nonprotocolized0/110 (0%)0/110 (0%)27/110 (24.5%)
Most frequent other events
Most frequent other events
EventProtocolizedNonprotocolized
NauseaGastrointestinal disorders11/645/56
Pulse rate <60 beats/minVascular disorders4/1069/106
PruritusSkin and subcutaneous tissue disorders7/1084/110
VomitingGastrointestinal disorders3/641/56
Oxygen saturation 90-94%Respiratory, thoracic and mediastinal disorders5/1082/110
Systolic blood pressure <90 mmHgVascular disorders2/1083/108
Oxygen saturation <90%Respiratory, thoracic and mediastinal disorders0/1082/110
Respiratory rate <12 breaths /minRespiratory, thoracic and mediastinal disorders1/1081/110

Baseline characteristics

The difference between the number of participants who enrolled and completed the study and the number of participants analyzed is due to missing outcome data. There were 4 missing data from the Protocolized group, and 2 missing data from the Nonprotocolized group, for a total of 6 patients. These 6 patients were excluded from the analysis.

Age, Continuous
Age, Continuous(years)ProtocolizedNonprotocolizedTotal
Mean40 ± 1141 ± 1241 ± 12
Sex: Female, Male
Sex: Female, Male(Participants)ProtocolizedNonprotocolizedTotal
Female6675141
Male423577
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)ProtocolizedNonprotocolizedTotal
Black253459
White9817
Hispanic7266138
Other224
Region of Enrollment
Region of Enrollment(Participants)ProtocolizedNonprotocolizedTotal
United States108110218
Weight
Weight(lbs)ProtocolizedNonprotocolizedTotal
Mean179 ± 52177 ± 49178 ± 51
Location of Pain
Location of Pain(Participants)ProtocolizedNonprotocolizedTotal
Abdomen5973132
Other493786
Pain Intensity
Pain Intensity(Participants)ProtocolizedNonprotocolizedTotal
3-781523
8222648
9111425
106755122
Nausea/vomiting
Nausea/vomiting(Participants)ProtocolizedNonprotocolizedTotal
Count of participants445498

1 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Montefiore Medical Center
    Bronx, New York 10467, United States
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 5, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00627367
Lead sponsor
Montefiore Medical Center
Responsible party
Andrew Chang, MD (MD, Montefiore Medical Center) — Principal investigator
First posted
Mar 3, 2008
Start date
Dec 2007
Primary completion
Mar 2008
Completion
Mar 2008
Results posted
Apr 5, 2018
Last update
Apr 5, 2018

Study contacts

Andrew Chang, M.D.
principal investigator · Montefiore Medical Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion